Previous 10 |
MEI Pharma (NASDAQ: MEIP ): Q2 GAAP EPS of -$0.15 misses by $0.01 . More news on: MEI Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its second quarter ended December 31, 2018 . "MEI remains in a strong position to continue to bui...
SAN DIEGO , Dec. 2, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that results from an ongoing Phase 1b study support the complementary potential of intermittent and continuou...
SAN DIEGO , Dec. 1, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of Hematology (ASH) annual meeting demonstrating that voruci...
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., the Company's president and chief executive officer, will present a corporate upd...
SAN DIEGO , and TOKYO , Nov. 5, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Hakko Kirin Co., Ltd. ( Tokyo : 4151, "Kyowa Hakko Kirin"), today announced the execution of a license agreement granting Kyowa Hakko Kirin exclusive rights to develop and commercialize ME...
SAN DIEGO , Nov. 1, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present data from three accepted abstracts related to MEI Pharma's clinical stage drug development...
News, Short Squeeze, Breakout and More Instantly...
Company Commences a Cash Preservation Plan Including a Reduction in Force MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including ...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...